GlassScriptPhysician profile
Patti A Anolik
NPI 1518222348
$2,117.93
in general payments reported to CMS, 2019-2025
18 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.56 · 2020: $94.34 · 2021: $247 · 2022: $207 · 2023: $674 · 2024: $456 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.58 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $482.31 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $170.32 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $141.86 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $141.08 | 2020-2025 | |
| Lilly USA, LLC | $140.17 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $65.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $48.53 | 2022 | |
| Amgen INC. | $48.00 | 2023-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $34.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.77 | 2019-2023 | Livalo |
| Bausch Health US, LLC | $21.58 | 2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $18.20 | 2025 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $13.53 | 2023 | Prehevbrio |
| Allergan, INC. | $13.42 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $13.31 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $12.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patti Anolik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.